GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Operating Cash Flow per Share

Telo Genomics (Telo Genomics) Operating Cash Flow per Share : $-0.03 (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics Operating Cash Flow per Share?

Telo Genomics's operating cash flow per share for the three months ended in Dec. 2023 was $-0.01. Telo Genomics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.03.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -5.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Telo Genomics's Operating Cash Flow per Share or its related term are showing as below:

TDSGF' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -172.3   Med: -3.9   Max: 64.5
Current: -5.9

During the past 12 years, Telo Genomics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 64.50% per year. The lowest was -172.30% per year. And the median was -3.90% per year.

TDSGF's 3-Year OCF Growth Rate is ranked worse than
62.86% of 175 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1 vs TDSGF: -5.90

Telo Genomics Operating Cash Flow per Share Historical Data

The historical data trend for Telo Genomics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Operating Cash Flow per Share Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.03 -0.02 -0.02 -0.03

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of Telo Genomics's Operating Cash Flow per Share

For the Diagnostics & Research subindustry, Telo Genomics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telo Genomics's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Price-to-Operating-Cash-Flow falls into.


Telo Genomics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Telo Genomics's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (A: Jun. 2023 )=Cash Flow from Operations (A: Jun. 2023 )/Shares Outstanding (Diluted Average) (A: Jun. 2023 )
=-1.98/60.152
=-0.03

Telo Genomics's Operating Cash Flow per Share for the quarter that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )=Cash Flow from Operations (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=-0.509/71.310
=-0.01

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Telo Genomics (Telo Genomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Operating Cash Flow per Share
Comparable Companies
XCNQ:SONA TSXV:AVCR XCNQ:IZO XCNQ:BUX TSXV:ARC TSX:SZLS TSXV:JUMP XCNQ:VTAL NEOE:MEDV TSXV:MBI.H TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
3D0A:Germany TELO:Canada
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Website
https://www.telodx.com
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.